MRI-based risk stratification for clinically significant prostate cancer detection at biopsy: The value of zonal-specific PSA density and PSHS
Integrating PI-RADS, PSAD-TZ, and PSHS may enhance risk stratification for csPCa at biopsy, enabling more precise identification of patients at an elevated risk who may require further evaluation. This approach may consequently reduce false-negative MRI results and facilitate more precise decision-making regarding biopsy indications.
Authors
- Niels J. Rupp (ORCID: https://orcid.org/0000-0002-7043-3456)
- Andreas M. Hötker (ORCID: https://orcid.org/0000-0002-4748-8758)
- Soleen Ghafoor (ORCID: https://orcid.org/0000-0002-8459-7363)
- Daniel Eberli (ORCID: https://orcid.org/0000-0001-8866-8010)
- Stefanie von Felten (ORCID: https://orcid.org/0000-0002-5264-6394)
- Antonia M. Pausch
- Rebecca Notter
- Stephan Benke-Bruderer
Institutions
- University of Zurich (CH)
- University Hospital of Zurich (CH)
Publication Details
- Journal
- European Journal of Radiology
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1016/j.ejrad.2025.111982
- Citations
- 3
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56